Table II.

Acute-phase proteinsa

DayPlacebo10 mg/kg cA2p Value
CRP (mg/L) n = 24 n = 24  
56, 33–70 65, 28–94  
52, 27–63 55, 22–71 0.05 
47, 31–74 22, 13–31 0.001 
56, 31–72 18, 13–35 0.001 
14 49, 29–72 19, 10–44 0.01 
28 60, 29–71 24, 13–50 0.001 
SAA (mg/ml) n = 24 n = 24  
335, 62–750 378, 180–935  
420, 127–755 380, 121–908 NS 
441, 115–890 50, 19–163 0.01 
378, 136–810 62, 26–206 0.01 
14 493, 228–853 56, 26–272 0.01 
28 720, 176–887 69, 22–345 0.01 
Haptoglobin (g/L) n = 20 n = 15  
3.4, 3.0–4.3 3.3, 2.7–3.7  
28 3.4, 3.0–4.3 2.5, 1.5–3.2 0.001 
Fibrinogen (g/L) n = 20 n = 14  
3.8, 3.4–5.0 4.1, 3.2–4.7  
28 4.0, 3.3–5.4 2.8, 2.2–3.1 0.002 
DayPlacebo10 mg/kg cA2p Value
CRP (mg/L) n = 24 n = 24  
56, 33–70 65, 28–94  
52, 27–63 55, 22–71 0.05 
47, 31–74 22, 13–31 0.001 
56, 31–72 18, 13–35 0.001 
14 49, 29–72 19, 10–44 0.01 
28 60, 29–71 24, 13–50 0.001 
SAA (mg/ml) n = 24 n = 24  
335, 62–750 378, 180–935  
420, 127–755 380, 121–908 NS 
441, 115–890 50, 19–163 0.01 
378, 136–810 62, 26–206 0.01 
14 493, 228–853 56, 26–272 0.01 
28 720, 176–887 69, 22–345 0.01 
Haptoglobin (g/L) n = 20 n = 15  
3.4, 3.0–4.3 3.3, 2.7–3.7  
28 3.4, 3.0–4.3 2.5, 1.5–3.2 0.001 
Fibrinogen (g/L) n = 20 n = 14  
3.8, 3.4–5.0 4.1, 3.2–4.7  
28 4.0, 3.3–5.4 2.8, 2.2–3.1 0.002 
a

The data are expressed as median, interquartile range. There were no significant differences between the two treatment groups for any measure prior to treatment. Values of p assess significance of the change from pretreatment values in the cA2 group compared with change in the placebo group by ANOVA (CRP, SAA) or Mann-Whitney U test (haptoglobin, fibrinogen). Normal ranges: CRP, <10 mg/L; SAA, <10 mg/L; haptoglobin, 0.7 –3.8 g/L; fibrinogen, 1.8 –3.5 g/L.

Close Modal

or Create an Account

Close Modal
Close Modal